Different anti-HCV profiles of statins and their potential for combination therapy with interferon

Masanori Ikeda, Ken Ichi Abe, Masashi Yamada, Hiromichi Dansako, Kazuhito Naka, Nobuyuki Kato

Research output: Contribution to journalArticle

238 Citations (Scopus)

Abstract

We recently developed a genome-length hepatitis C virus (HCV) RNA replication system (OR6) with luciferase as a reporter. The OR6 assay system has enabled prompt and precise quantification of HCV RNA replication. Pegylated interferon (IFN) and ribavirin combination therapy is the world standard for chronic hepatitis C, but its effectiveness is limited to about 55% of patients. Newer therapeutic approaches are needed. In the present study, we used the OR6 assay system to evaluate the anti-HCV activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, called statins, and their effects in combination with IFN-α. Five types of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) were examined for their anti-HCV activities. Fluvastatin exhibited the strongest anti-HCV activity (IC 50: 0.9 μmol/L), whereas atorvastatin and simvastatin showed moderate inhibitory effects. However, lovastatin, reported recently as an inhibitor of HCV replication, was shown to exhibit the weakest anti-HCV activity. The anti-HCV activities of statins were reversed by the addition of mevalonate or geranylgeraniol. Surprisingly, however, pravastatin exhibited no anti-HCV activity, although it worked as an inhibitor for HMG-CoA reductase. The combination of IFN and the statins (except for pravastatin) exhibited strong inhibitory effects on HCV RNA replication. In combination with IFN, fluvastatin also exhibited a synergistic inhibitory effect. In conclusion, statins, especially fluvastatin, could be potentially useful as new anti-HCV reagents in combination with IFN.

Original languageEnglish
Pages (from-to)117-125
Number of pages9
JournalHepatology
Volume44
Issue number1
DOIs
Publication statusPublished - Jul 2006

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hepacivirus
Interferons
fluvastatin
Virus Replication
Pravastatin
Therapeutics
Lovastatin
Simvastatin
RNA
Oxidoreductases
Mevalonic Acid
Ribavirin
Chronic Hepatitis C
Coenzyme A
Luciferases

ASJC Scopus subject areas

  • Hepatology

Cite this

Different anti-HCV profiles of statins and their potential for combination therapy with interferon. / Ikeda, Masanori; Abe, Ken Ichi; Yamada, Masashi; Dansako, Hiromichi; Naka, Kazuhito; Kato, Nobuyuki.

In: Hepatology, Vol. 44, No. 1, 07.2006, p. 117-125.

Research output: Contribution to journalArticle

Ikeda, Masanori ; Abe, Ken Ichi ; Yamada, Masashi ; Dansako, Hiromichi ; Naka, Kazuhito ; Kato, Nobuyuki. / Different anti-HCV profiles of statins and their potential for combination therapy with interferon. In: Hepatology. 2006 ; Vol. 44, No. 1. pp. 117-125.
@article{597d0d519f924d12aaa0bc54d2807964,
title = "Different anti-HCV profiles of statins and their potential for combination therapy with interferon",
abstract = "We recently developed a genome-length hepatitis C virus (HCV) RNA replication system (OR6) with luciferase as a reporter. The OR6 assay system has enabled prompt and precise quantification of HCV RNA replication. Pegylated interferon (IFN) and ribavirin combination therapy is the world standard for chronic hepatitis C, but its effectiveness is limited to about 55{\%} of patients. Newer therapeutic approaches are needed. In the present study, we used the OR6 assay system to evaluate the anti-HCV activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, called statins, and their effects in combination with IFN-α. Five types of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) were examined for their anti-HCV activities. Fluvastatin exhibited the strongest anti-HCV activity (IC 50: 0.9 μmol/L), whereas atorvastatin and simvastatin showed moderate inhibitory effects. However, lovastatin, reported recently as an inhibitor of HCV replication, was shown to exhibit the weakest anti-HCV activity. The anti-HCV activities of statins were reversed by the addition of mevalonate or geranylgeraniol. Surprisingly, however, pravastatin exhibited no anti-HCV activity, although it worked as an inhibitor for HMG-CoA reductase. The combination of IFN and the statins (except for pravastatin) exhibited strong inhibitory effects on HCV RNA replication. In combination with IFN, fluvastatin also exhibited a synergistic inhibitory effect. In conclusion, statins, especially fluvastatin, could be potentially useful as new anti-HCV reagents in combination with IFN.",
author = "Masanori Ikeda and Abe, {Ken Ichi} and Masashi Yamada and Hiromichi Dansako and Kazuhito Naka and Nobuyuki Kato",
year = "2006",
month = "7",
doi = "10.1002/hep.21232",
language = "English",
volume = "44",
pages = "117--125",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Different anti-HCV profiles of statins and their potential for combination therapy with interferon

AU - Ikeda, Masanori

AU - Abe, Ken Ichi

AU - Yamada, Masashi

AU - Dansako, Hiromichi

AU - Naka, Kazuhito

AU - Kato, Nobuyuki

PY - 2006/7

Y1 - 2006/7

N2 - We recently developed a genome-length hepatitis C virus (HCV) RNA replication system (OR6) with luciferase as a reporter. The OR6 assay system has enabled prompt and precise quantification of HCV RNA replication. Pegylated interferon (IFN) and ribavirin combination therapy is the world standard for chronic hepatitis C, but its effectiveness is limited to about 55% of patients. Newer therapeutic approaches are needed. In the present study, we used the OR6 assay system to evaluate the anti-HCV activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, called statins, and their effects in combination with IFN-α. Five types of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) were examined for their anti-HCV activities. Fluvastatin exhibited the strongest anti-HCV activity (IC 50: 0.9 μmol/L), whereas atorvastatin and simvastatin showed moderate inhibitory effects. However, lovastatin, reported recently as an inhibitor of HCV replication, was shown to exhibit the weakest anti-HCV activity. The anti-HCV activities of statins were reversed by the addition of mevalonate or geranylgeraniol. Surprisingly, however, pravastatin exhibited no anti-HCV activity, although it worked as an inhibitor for HMG-CoA reductase. The combination of IFN and the statins (except for pravastatin) exhibited strong inhibitory effects on HCV RNA replication. In combination with IFN, fluvastatin also exhibited a synergistic inhibitory effect. In conclusion, statins, especially fluvastatin, could be potentially useful as new anti-HCV reagents in combination with IFN.

AB - We recently developed a genome-length hepatitis C virus (HCV) RNA replication system (OR6) with luciferase as a reporter. The OR6 assay system has enabled prompt and precise quantification of HCV RNA replication. Pegylated interferon (IFN) and ribavirin combination therapy is the world standard for chronic hepatitis C, but its effectiveness is limited to about 55% of patients. Newer therapeutic approaches are needed. In the present study, we used the OR6 assay system to evaluate the anti-HCV activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, called statins, and their effects in combination with IFN-α. Five types of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) were examined for their anti-HCV activities. Fluvastatin exhibited the strongest anti-HCV activity (IC 50: 0.9 μmol/L), whereas atorvastatin and simvastatin showed moderate inhibitory effects. However, lovastatin, reported recently as an inhibitor of HCV replication, was shown to exhibit the weakest anti-HCV activity. The anti-HCV activities of statins were reversed by the addition of mevalonate or geranylgeraniol. Surprisingly, however, pravastatin exhibited no anti-HCV activity, although it worked as an inhibitor for HMG-CoA reductase. The combination of IFN and the statins (except for pravastatin) exhibited strong inhibitory effects on HCV RNA replication. In combination with IFN, fluvastatin also exhibited a synergistic inhibitory effect. In conclusion, statins, especially fluvastatin, could be potentially useful as new anti-HCV reagents in combination with IFN.

UR - http://www.scopus.com/inward/record.url?scp=33745903898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745903898&partnerID=8YFLogxK

U2 - 10.1002/hep.21232

DO - 10.1002/hep.21232

M3 - Article

C2 - 16799963

AN - SCOPUS:33745903898

VL - 44

SP - 117

EP - 125

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 1

ER -